ESTUTC-5 New YorkLog in Sign up

MBRX
Moleculin Biotech, Inc.
stockNASDAQ

Market OpenNov 10, 2026 1:42:00 PM EST

8.75USD+1.039%(+0.09)7,738

7.2300Bid11.13Ask3.9000Spread

MBRX News

Day breaks

11:26 AM ESTMoleculin Biotech (MBRX) Reports Promising Interim AML Trial Results Ahead of ASH 2026 ·

GuruFocus

11:00 AM ESTMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting ·

GlobeNewswire Inc.

08:40 AM EDTMoleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 ·

GlobeNewswire Inc.

08:20 AM EDTMoleculin Biotech completes enrollment in AML trial phase ·

Investing.com

08:12 AM EDTMoleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial ·

GlobeNewswire Inc.

09:32 AM EDTMoleculin announces 1-for-20 reverse stock split, shares slide ·

Seeking Alpha

09:20 AM EDTMoleculin Announces Reverse Stock Split ·

GlobeNewswire Inc.

08:45 AM EDTMoleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit ·

GlobeNewswire Inc.

08:45 AM EDTMoleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout ·

GlobeNewswire Inc.

07:00 AM EDTMoleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine ·

GlobeNewswire Inc.

01:05 PM EDTAnnamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR ·

GlobeNewswire Inc.

08:25 AM EDTMoleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 ·

GlobeNewswire Inc.

05:31 PM EDTMoleculin Biotech receives Nasdaq delisting notice after minimum bid price violation ·

Investing.com